Work

28P Decoding biomarkers of immune activation in neuroendocrine carcinomas treated with ipilimumab and nivolumab using a multiomic approach

Year: 2024

Type: article

Abstract: The S1609 DART trial is designed to assess the clinical relevance of combination dual ipilimumab and nivolumab in rare tumors. We focused on immune profiling 2 cohorts comprised of subtypes of neuroendocrine carcinomas; cohort 23 (nonpancreatic neuroendocrine (NET) and cohort 52 (pan high-grade neuroendocrine).

Source: ESMO Open

DOI: 10.1016/j.esmoop.2024.102417

Authors: C. Haymaker, G. Kumar, Y.K. Chae, E. Gonzalez-Kozlova, C. Duault, J. Zhang, M. Othus, L. Solis Soto, G. Manyam, P. Jiang, E.R. Parra, C. Laberiano Fernandez, A. Reuben, H. Maecker, S. Gnjatic, G. Al-Atrash, J. Zhang, J.J. Lee, S.P. Patel, R. Kurzrock

Institutions: The University of Texas MD Anderson Cancer Center, Northwestern University, Icahn School of Medicine at Mount Sinai, Stanford Medicine, Stanford University, Fred Hutch Cancer Center, University of California San Diego, Moores Cancer Center, Froedtert Hospital, Medical College of Wisconsin, Medical College of Wisconsin Cancer Center

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,730

Funders: Bristol-Myers Squibb, Icahn School of Medicine at Mount Sinai, National Cancer Institute

Awards: G4847734291, G6651326882, G8608891112

OpenAlex ID: W4392880878

FWCI:

Cites:

Cited by:

Related to: 10